Looking At BioNTech's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards BioNTech BNTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BNTX usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for BioNTech. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable options, 6 are puts, totaling $283,790, and 2 are calls, amounting to $87,000.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $95.0 and $180.0 for BioNTech, spanning the last three months.

Volume & Open Interest Trends

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in BioNTech's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to BioNTech's substantial trades, within a strike price spectrum from $95.0 to $180.0 over the preceding 30 days.

BioNTech Option Volume And Open Interest Over Last 30 Days

Noteworthy Options Activity:

About BioNTech

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

In light of the recent options history for BioNTech, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Current Position of BioNTech

• With a volume of 941,011, the price of BNTX is up 0.33% at $97.37.
• RSI indicators hint that the underlying stock may be approaching oversold.
• Next earnings are expected to be released in 40 days.

Expert Opinions on BioNTech

A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $149.61.

Unusual Options Activity Detected: Smart Money on the Move

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Canaccord Genuity persists with their Buy rating on BioNTech, maintaining a target price of $171. * Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on BioNTech with a target price of $143. * An analyst from Citigroup downgraded its action to Buy with a price target of $145. * Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on BioNTech with a target price of $139.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest BioNTech options trades with real-time alerts from Benzinga Pro.